Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.

Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci Rep (2017) 0.77

Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet (2007) 8.55

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99

Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09

Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85

Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55

The biology and life-cycle of human papillomaviruses. Vaccine (2012) 2.53

Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol (2008) 2.37

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31

Production of papillomavirus-based gene transfer vectors. Curr Protoc Cell Biol (2007) 2.25

Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol (2001) 2.02

Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology (2006) 1.65

A note on some points of calculation method of LD50 by Reed and Muench. Jpn J Exp Med (1949) 1.64

Human papillomavirus vaccines--immune responses. Vaccine (2012) 1.40

Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm (2010) 1.31

Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology (2004) 1.13

Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health (2015) 1.13

Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine (2012) 1.09

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol (2008) 1.01

Dual- and triple-color fluorospot. Methods Mol Biol (2012) 0.97

Detection of HPV types and neutralizing antibodies in Gansu province, China. J Med Virol (2009) 0.94

High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One (2013) 0.93

The first international standard for antibodies to HPV 16. Vaccine (2011) 0.92

Uptake of the human papillomavirus vaccine: a review of the literature and report of a quality assurance project. J Pediatr Health Care (2010) 0.87

Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein. Virology (2005) 0.84

Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China. Virol Sin (2010) 0.81

Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types. J Immunol Methods (2014) 0.78

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Hum Vaccin Immunother (2014) 0.77

Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons. J Med Virol (2014) 0.77

Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay. J Immunol (2015) 0.77